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Abstract
Activity of H3K9 histone methyltransferase G9a is reportedly induced by transforming
growth factor-β1 (TGF-β1) and plays an important role in the progression of cancer and
fibrosis. In this study, we investigated whether inhibition of G9a-mediated H3K9 methylation
attenuates peritoneal fibrosis in mice and human peritoneal mesothelial cells (HPMCs).
Nonadherent cells of peritoneal dialysis (PD) patients were isolated from PD effluent to
examine expression of G9a. Peritoneal fibrosis was induced by peritoneal injection of
methylglyoxal (MGO) in male C57/B6 mice for 3 weeks. BIX01294, a G9a inhibitor, was
administered by subcutaneous injection. Effects of BIX01294 on MGO-induced pathological
and functional changes in mice were evaluated by immunohistochemistry and a peritoneal
equilibration test. HPMCs were isolated from human omentum, and the inhibitory effect of
BIX01294 on TGF-β1-induced fibrotic changes was investigated in the HPMCs by western
blotting. G9a was upregulated in nonadherent cells of human PD effluent, the peritoneum of
MGO-injected mice, and TGF-β1-stimulated HPMCs. BIX01294 significantly reduced the
submesothelial zone thickness and cell density in MGO-injected mice. Immunohistochemi-
cal staining revealed that BIX01294 treatment decreased not only mono-methylation of
H3K9 (H3K9me1), but also the number of mesenchymal cells, accumulation of collagen,
and infiltration of monocytes. In addition to the pathological changes, BIX01294 reduced the
level of TGF-β1 in peritoneal fluid and improved peritoneal functions. Furthermore,
BIX01294 inhibited TGF-β1-induced fibrotic changes along with suppression of H3K9me1
in HPMCs. Therefore, inhibition of H3K9 methyltransferase G9a suppresses peritoneal
fibrosis through a reduction of H3K9me1.
Introduction
Peritoneal dialysis (PD) is an effective replacement therapy for end-stage kidney disease, and
many patients benefit from PD treatment. However, long-term exposure to PD fluid eventu-
ally leads to peritoneal fibrosis that is clinically observed as a decrease in water removal [1, 2].
According to previous studies, glucose-driven glucose degradation products (GDPs)
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participate in this process [3–5]. In fact, among GDPs, the methylglyoxal (MGO) level is
reportedly increased in the serum and PD fluid of PD patients, playing a major role in the
development of peritoneal fibrosis [6–8]. However, a therapeutic strategy for MGO-induced
peritoneal fibrosis has not been established thus far.
Although numerous cytokines have been reported to participate in the progression of peri-
toneal fibrosis, an increase in transforming growth factor-β1 (TGF-β1) is well known in PD
effluents, which plays a pivotal role in this process [9–11]. The pathogenesis of peritoneal
fibrosis is characterized by loss of the properties of peritoneal cells, transdifferentiation into
myofibroblasts, and production of excessive amounts of extracellular matrix (ECM) [12, 13]. If
these processes are classified by transcriptional activity, the loss of cell properties can be classi-
fied as decreased transcriptional activity, while fibroblast property acquisition and extracellular
matrix protein production can be classified as enhanced transcriptional activity.
Epigenetics are defined as a regulation system of gene expression without changing DNA
sequences [14, 15]. A previous study has revealed that changes in gene expression patterns are
the true cause of fibrosis, and not changes in DNA sequences [16, 17]. Among epigenetic regu-
lations, methylation of the histone tail is regulated by specific enzymes [18], indicating that
TGF-β1-induced histone methyltransferases are therapeutic targets for peritoneal fibrosis.
Recently, we have demonstrated that TGF-β1-induced G9a is responsible for renal fibrosis
through mono-methylation of lysine 9 in histone H3 (H3K9me1), but not di-methylation
(H3K9me2) [19]. G9a-induced H3K9 methylation causes transcriptional silencing [20], raising
the possibility that BIX01294, a selective inhibitor of G9a, can suppress the loss of cellular
properties and subsequent fibrotic processes through inhibition of H3K9me1.
In this study, we show upregulation of G9a in nonadherent cells isolated from PD effluent,
MGO-injected mice, and TGF-β1-induced primary human peritoneal mesothelial cells
(HPMCs). We also show that BIX01294 reduces pathological damage and peritoneal dysfunc-
tion along with inhibition of H3K9me1 in MGO-injected mice. In HPMCs, BIX01294 attenu-
ates TGF-β1-induced fibrotic changes with a decrease in H3K9me1. Our findings indicate
upregulation of G9a in response to TGF-β1 stimulation in not only MGO-injected mice, but
also PD patients, and that BIX01294 suppresses peritoneal fibrosis through the reduction of
H3K9me1 in vitro and in vivo.
Materials and methods
Animal model
Ten-week-old male C57BL/6 mice weighting of 20–25 g were purchased from Charles River
Laboratories Japan (Yokohama, Japan). The animals had free access to laboratory chow and
tap water, and were housed in a light- and temperature-controlled room at the Laboratory
Animal Center of Hiroshima University (Hiroshima, Japan). The mice were divided into three
groups (n = 5 per group) that received (1) intraperitoneal injection of 2.5 mL saline (control
mice), (2) intraperitoneal injection of 40 mM MGO (MP Biomedicals LLC, Illkirch, France)
+ subcutaneous injection of saline (MGO mice), or (3) intraperitoneal injection of 40 mM
MGO + subcutaneous injection of 75 μg/day BIX01294 (Sigma-Aldrich, St Louis, MO, USA)
(MGO + BIX01294 mice). Peritoneal fibrosis was induced by intraperitoneal injection of 40
mM MGO in 2.5 mL saline [21]. BIX01294 at 75 μg/day in 0.1 mL saline was administrated by
subcutaneous injection just before MGO injection. These solutions were administered for 5
consecutive days of the week for 3 weeks.
For the peritoneal equilibrium test (PET), mice were instilled with 4 mL of a PD solution
(4.25% Dianeal; Baxter Health Care, Deerfield, IL, USA) before sacrifice by cardiac puncture.
After 10 minutes, the peritoneal fluid was removed and blood samples were obtained by
G9a-induced H3K9me1 in peritoneal fibrosis
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cardiac puncture under sedation by sodium pentobarbital anesthesia. The peritoneal perme-
abilities of glucose and blood urea nitrogen were expressed as the peritoneal absorption of glu-
cose from the dialysate and the dialysate-to-plasma ratio of blood urea nitrogen, respectively.
Parietal peritoneum samples were obtained from the contralateral side of injection.
The experimental protocol was approved by the Animal Care and Use Committee of Hiro-
shima University (permit number: A14-48). All animal experiments were performed in accor-
dance with the National Institutes of Health Guidelines on the Use of Laboratory Animals.
Histology and immunohistochemistry
Histology and immunohistochemical staining of 4-μm-thick tissue sections were performed as
described previously [22]. The following primary antibodies were used: rabbit polyclonal anti-
G9a antibody (Abcam, Cambridge, UK), mouse monoclonal anti-α-smooth muscle actin
(SMA) antibody (Sigma-Aldrich), rabbit polyclonal anti-collagen I antibody (Abcam), rabbit
polyclonal anti-collagen III antibody (Abcam), rat monoclonal anti-mouse CD68 antibody
(Serotec, Oxford, UK), rabbit polyclonal anti-TGF-β1 antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), and rabbit polyclonal anti-H3K9me1 antibody (Abcam).
The numbers of cells positive for α-SMA, CD68, TGF-β1, and H3K9me1 in the subme-
sothelial compact zone were counted in 10 fields at ×200 magnification. Areas containing col-
lagen I and III were assessed at ×200 magnification in predetermined fields of the
submesothelial compact zone captured by a digital camera and analyzed using ImageJ software
(version 1.48p; National Institutes of Health, Bethesda, MD, USA) in 10 fields.
Cell culture of HPMCs
HPMCs were isolated from human omentum as described previously [23]. Harvesting of the
omentum was permitted by the Medical Ethics Committee of Hiroshima Graduate School of
Biomedical Science (E-84). Written Informed consent was obtained from each patient.
HPMCs were maintained in M199 medium (Life Technologies, New York City, NY, USA)
containing 10% fetal bovine serum (FBS) and penicillin/streptomycin. The cells were seeded into
six-well plates. At subconfluence, HPMCs were growth arrested for 24 hours in M199 medium
containing 0.1% FBS and then treated with 5 ng/mL TGF-β1 (R&D Systems, Minneapolis, MN,
USA) for 0–24 hours. Preincubation with 2 μmol/L BIX01294 was carried out for 60 minutes
before the 24 hours of TGF-β1 stimulation. We repeated five times of cell culture experiment.
Western blot analysis and Enzyme-Linked Immunosorbent Assay
(ELISA)
Western blot analysis was performed as described previously [24]. Detection of secreted fibro-
nectin was performed as described previously [25]. Each group included five samples. Primary
antibodies used in this study were anti-G9a (Cell Signaling Technology, Danvers, MA, USA),
anti-α-SMA (Sigma-Aldrich), anti-zonula occludens-1 (ZO-1; Invitrogen, Carlsbad, CA,
USA), anti-fibronectin (Sigma-Aldrich), anti-α-tubulin (Sigma-Aldrich), anti-H3K9me1 (Cell
Signaling Technology), and anti-H3 (Cell Signaling Technology). The intensity of each band
was determined using ImageJ software. Concentrations of TGF-β1 in peritoneal fluid were
measured with an ELISA (R&D Systems), following the manufacturer’s instructions.
Clinical sample collection and ethics statement
To culture nonadherent cells in PD effluent, cells were isolated from spent glucose-based PD
fluid (1.5% Dianeal) from three clinically stable PD patients at Hiroshima University Hospital
G9a-induced H3K9me1 in peritoneal fibrosis
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from September 2015 to March 2016. HPMCs were used as the control. This study was
approved by the Medical Ethics Committee of Hiroshima Graduate School of Biomedical Sci-
ence (E-62) and was conducted in accordance with the Declaration of Helsinki. Written
informed consent was obtained from each patient.
Statistical analysis
The results are expressed as the mean ± standard error (SE). Comparisons between two groups
were performed using the Student’s t-test, whereas those among three groups were performed
by analysis of variance followed by Tukey’s post-hoc test. A value of P< 0.05 was considered
statistically significant.
Results
G9a expression is upregulated in a mouse model of peritoneal fibrosis
and in human PD effluent
To examine G9a expression in the progression of peritoneal fibrosis, we first performed immu-
nohistochemical staining of G9a in MGO mice. In contrast to few cells expressing G9a in con-
trol mice, we found accumulation of G9a-positive cells in the submesothelial zone of MGO mice
(Fig 1A and 1B). In nonadherent cells of human PD effluents, we found elevation of G9a expres-
sion levels in PD patients compared with HPMCs derived from non-PD patients (Fig 1C).
Fig 1. G9a expression is upregulated in MGO-injected mice and human Peritoneal Dialysis (PD)
effluents. (A) Immunohistochemical staining shows typical G9a expression in peritoneal tissues of control
mice and methylglyoxal (MGO)-injected mice (original magnification, ×200). (B) Graph indicating the number
of G9a-positive cells in mice with or without peritoneal injection of MGO (n = 5 for both groups). (C)
Representative western blot analysis showing the levels of G9a expression in nonadherent cells of human PD
effluents. Data are expressed as the mean ± SE. Statistical analysis was performed by the Student’s t-test.
*P < 0.05.
doi:10.1371/journal.pone.0173706.g001
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BIX01294 suppresses the thickening and accumulation of peritoneal
cells induced by MGO
Masson’s trichrome staining was used to analyze the peritoneal thickness, and hematoxylin-
eosin staining was used to assess changes in cell density. In control mice, the peritoneal tissues
were almost normal without thickening of the submesothelial compact zone. Compared with
control mice, the submesothelial compact zone in the peritoneum of MGO mice was signifi-
cantly thicker and enriched with numerous cells. However, subcutaneous injection of
BIX01294 suppressed the thickening of the submesothelial compact zone (Fig 2A and 2B) and
the presence of peritoneal cells (Fig 2C and 2D).
BIX01294 attenuates expression of a mesenchymal marker and ECM
proteins in mice with peritoneal fibrosis
We examined peritoneal expression of α-SMA as a mesenchymal marker. In MGO mice,
numerous α-SMA-positive myofibroblasts were identified in the markedly thickened subme-
sothelial compact zone. BIX01294 administration significantly decreased the number of α-
SMA-positive myofibroblasts compared with MGO mice (Fig 3A and 3B).
Collagen I and III are well-known ECM proteins. Although collagen I and III were diffusely
expressed in the submesothelial compact zone of MGO mice (Fig 4A and 4C), BIX01294
administration significantly reduced the area of collagen I and III expression (Fig 4B and 4D).
BIX01294 inhibits infiltration of monocytes/macrophages, TGF-β1
signaling, and G9a-mediated H3K9me1
We examined CD68 expression to investigate monocyte/macrophage infiltration into the peri-
toneum. The number of CD68-positive cells in the submesothelial compact zone of MGO
Fig 2. BIX01294 suppresses peritoneal thickening and cell density in MGO-injected mice. (A) Masson’s trichrome
staining shows the typical thickness of peritoneal tissue in control mice, MGO-injected mice, and MGO-injected mice
treated with BIX01294 (original magnification, ×200). (B) Graph indicates quantification of the peritoneal thickness in the
three groups of mice. (C) Hematoxylin-eosin staining shows typical cellularity of peritoneal tissue in control mice, MGO-
injected mice, and MGO-injected mice treated with BIX01294 (original magnification, ×200). (D) Graph indicates
quantification of cell density in the three groups of mice. Data are expressed as the mean ± SE. Statistical analysis was
performed by analysis of variance followed by Tukey’s post-hoc test. *P < 0.05, n = 5 mice per group.
doi:10.1371/journal.pone.0173706.g002
G9a-induced H3K9me1 in peritoneal fibrosis
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mice was markedly greater than that in control mice. BIX01294 administration significantly
decreased the number of CD68-positive cells compared with MGO mice (Fig 5A and 5B). Sim-
ilarly, the number of TGF-β1-positive cells in the submesothelial compact zone of MGO mice
was markedly greater than that in control mice. Compared with MGO mice, BIX01294 admin-
istration decreased the number of TGF-β1-positive cells (Fig 5C and 5D). Most CD68-positive
cells showed immunoreactivity for TGF-β1 (Fig 5E, arrows), demonstrating colocalization of
CD68 and TGF-β1. The concentrations of TGF-β1 were measured in mouse PD effluent. Pro-
tein levels of TGF-β1 in MGO mice were significantly increased in comparison with control
mice, but they were dramatically reduced in MGO + BIX01294 mice (Fig 5F). The number of
H3K9me1-positive cells in the submesothelial compact zone of MGO mice was markedly
larger than that in control mice, and BIX01294 administration significantly decreased the
number of H3K9me1-positive cells (Fig 5G and 5H).
Fig 3. BIX01294 attenuates α-Smooth Muscle Actin (α-SMA) expression in mice with peritoneal fibrosis. (A)
Immunohistochemical staining shows typical α-SMA expression in peritoneal tissue of control mice, MGO-injected mice,
and MGO-injected mice treated with BIX01294 (original magnification, ×200). (B) Graph indicates the number of α-SMA-
positive cells in the three groups of mice. Data are expressed as the mean ± SE. Statistical analysis was performed by
analysis of variance followed by Tukey’s post-hoc test. *P < 0.05, n = 5 mice per group.
doi:10.1371/journal.pone.0173706.g003
Fig 4. BIX01294 reduces collagen I and III expression in mice with peritoneal fibrosis. (A) Immunohistochemical
staining shows typical collagen I expression in peritoneal tissue of control mice, MGO-injected mice, and MGO-injected
mice treated with BIX01294 (original magnification, ×200). (B) Graph indicates the number of collagen I-positive pixels in
the three groups of mice. (C) Immunohistochemical staining shows typical collagen III expression in the peritoneal tissue of
control mice, MGO-injected mice, and MGO-injected mice treated with BIX01294 (original magnification, ×200). (D) Graph
indicates the number of collagen III-positive pixels in the three groups of mice. Data are expressed as the mean ± SE.
Statistical analysis was performed by analysis of variance followed by Tukey’s post-hoc test. *P < 0.05, n = 5 mice per
group.
doi:10.1371/journal.pone.0173706.g004
G9a-induced H3K9me1 in peritoneal fibrosis
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BIX01294 decreases functional impairments of the peritoneal membrane
in mice with peritoneal fibrosis
A PET was performed to assess functional alterations of the peritoneal membrane. MGO
induced a significant increase in permeability for blood urea nitrogen compared with control
mice (Fig 6A). In contrast, this change was significantly attenuated in MGO + BIX01294 mice
(Fig 6A). In addition, glucose absorption was increased in MGO mice compared with control
mice, and significantly improved in MGO + BIX01294 mice (Fig 6B).
Fig 5. BIX01294 inhibits monocyte/macrophage infiltration, TGF-β1, and H3K9me1 in mice with peritoneal
fibrosis. (A) Immunohistochemical staining shows typical CD68 expression in peritoneal tissue of control mice, MGO-
injected mice, and MGO-injected mice treated with BIX01294 (original magnification, ×200). (B) Graph indicates the
number of CD68-positive cells in the three groups of mice. (C) Immunohistochemical staining shows typical TGF-β1
expression in peritoneal tissue of control mice, MGO-injected mice, and MGO-injected mice treated with BIX01294
(original magnification, ×200). (D) Graph indicates the number of TGF-β1-positive cells in the three groups of mice. (E)
Two-color immunohistochemical staining shows that most CD68 cells (brown) are immunoreactive for TGF-β1 (blue-gray)
(arrows). (F) TGF-β1 protein levels in mouse PD effluent were quantified by ELISA. (G) Immunohistochemical staining
shows typical H3K9me1 levels in peritoneal tissue of control mice, MGO-injected mice, and MGO-injected mice treated
with BIX01294 (original magnification, ×200). (H) Graph indicates the number of H3K9me1-positive cells in the three
groups of mice. Data are expressed as the mean ± SE. Statistical analysis were performed by analysis of variance followed
by Tukey’s post-hoc test. *P < 0.05, n = 5 mice per group.
doi:10.1371/journal.pone.0173706.g005
G9a-induced H3K9me1 in peritoneal fibrosis
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G9a expression is regulated by TGF-β1 in HPMCs and BIX01294
represses TGF-β1-induced fibrotic changes of HPMCs
TGF-β1 induces fibrotic changes in HPMCs, which are responsible for peritoneal fibrosis and
the failure of ultrafiltration. Therefore, we examined the role of TGF-β1 in G9a expression of
HPMCs. G9a protein was hardly expressed in control HPMCs, but it was upregulated over
time (Fig 7A). Next, to investigate the effects of BIX01294 on fibrotic changes in HPMCs, the
cells were stimulated with TGF-β1 with or without BIX01294 for 24 hours. TGF-β1 stimulation
increased α-SMA and fibronectin expression, and decreased ZO-1 protein expression.
BIX01294 treatment suppressed these TGF-β1-induced fibrotic responses (Fig 7B–7D). The
levels of H3K9me1 were increased by TGF-β1 stimulation, and BIX01294 treatment decreased
the levels of H3K9me1 (Fig 7E).
Discussion
In the present study, we found increased expression of G9a in not only a mouse model of MGO-
induced peritoneal fibrosis, but also nonadherent cells isolated from PD effluent of patients. We
also demonstrated that BIX01294, a selective inhibitor of G9a, suppresses peritoneal fibrosis and
peritoneal dysfunctions, which is accompanied by inhibition of H3K9me1. Expression of TGF-
β1 increased in the fibrotic area and PD effluent of MGO mice, and its expression was coloca-
lized with infiltrated macrophages. In the in vitro experiments, G9a was upregulated by TGF-β1
stimulation and BIX01294 inhibited TGF-β1-induced fibrotic changes in HPMCs along with
suppression of H3K9me1. These results suggest that BIX01294 is a candidate therapeutic agent
to prevent peritoneal fibrosis through suppression of G9a-mediated H3K9me1.
Among epigenetic changes, histone modifications cause chromatin remodeling, resulting
in activation or inactivation of gene expression [26]. Recently, several studies have revealed
that histone modification participates in various diseases [27]. In terms of peritoneal fibrosis,
previous studies have reported that a histone acetyltransferase inhibitor, C646, suppresses
TGF-β1-induced fibrotic changes in HPMCs [28], and that suberoylanilide hydroxamic acid, a
histone deacetylase inhibitor, attenuates peritoneal fibrosis in mice via induction of bone
Fig 6. BIX01294 improves functional impairments of the peritoneal membrane in mice with peritoneal
fibrosis. Graph shows (A) the dialysate-to-plasma (D/P) ratio of blood urea nitrogen (BUN) and (B) peritoneal
absorption of glucose from the dialysate (D/D0) in control mice, MGO-injected mice, and MGO-injected mice
treated with BIX01294 during the 10-minute dwell of dialysate (4.25% Dianeal). Data are expressed as the
mean ± SE. Statistical analysis were performed by analysis of variance followed by Tukey’s post-hoc test.
*P < 0.05, n = 5 mice per group.
doi:10.1371/journal.pone.0173706.g006
G9a-induced H3K9me1 in peritoneal fibrosis
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morphogenetic protein (BMP)-7 [29]. Notably, our previous report demonstrated that TGF-
β1-induced H3K9me1 is responsible for the progression of renal fibrosis [19]. Because histone
methylation is regulated by specific enzymes, its regulation is considered to be a more specific
therapy for peritoneal fibrosis than regulation of enzymes involved in other histone modifica-
tions. Furthermore, G9a is reported to induce di-methylation of H3K9me2 [30], but the level
of H3K9me2 was not increased by TGF-β1 stimulation, and BIX01294 treatment did not affect
Fig 7. G9a expression is regulated by TGF-β1 in HPMCs, and BIX01294 represses TGF-β1-induced fibrotic
changes. (A) Representative western blot analysis showing the levels of G9a protein expression in TGF-β1 (5 ng/
mL)-stimulated HPMCs at various time points. Quantification is shown in the lower panel. (B) Representative western
blot analysis of the expression of α-SMA (C) zonula occludens-1 (ZO-1), and (D) secreted fibronectin of HPMCs.
Quantification is shown in the lower panel. (E) Representative western blot analysis showing the levels of H3K9me1
in TGF-β1-stimulated in HPMCs. Quantification is shown in the lower panel. Data are expressed as the mean ± SE.
Statistical analysis was performed by analysis of variance followed by Tukey’s post-hoc test. *P < 0.05, n = 5
samples per group.
doi:10.1371/journal.pone.0173706.g007
G9a-induced H3K9me1 in peritoneal fibrosis
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the level of H3K9me2 in HPMCs (data not shown). These findings suggest that pharmacologi-
cal inhibition of H3K9 methyltransferase G9a ameliorates peritoneal fibrosis through a reduc-
tion in H3K9me1.
During the progression of peritoneal fibrosis, TGF-β1-stimulated peritoneal mesothelial
cells transdifferentiate into myofibroblasts, contributing to overproduction of ECM proteins.
These processes have been experimentally found to be caused by decreased expression of the
tight junction protein ZO-1, and increased expression of α-SMA and secretion of fibronectin.
The present data show that BIX01294 suppresses the TGF-β1-induced changes in HPMCs
along with a reduction of H3K9me1 expression, suggesting that G9a-mediated H3K9me1 reg-
ulates ZO-1 expression negatively while regulating expression of α-SMA and fibronectin posi-
tively. Moreover, we found an increase of G9a expression in the peritoneum of MGO mice
and in human PD effluents. Although we investigated whether TGF-β1 induces G9a expres-
sion in the human monocyte/macrophage cell line THP-1, we did not identify any effect of
TGF-β1 on G9a expression in inflammatory cells (data not shown). Therefore, detached peri-
toneal mesothelial cells, but not inflammatory cells, may be the majority of G9a-expressing
nonadherent cells.
In this study, we demonstrated that the G9a inhibitor attenuated not only MGO-induced
peritoneal fibrosis, but also TGF-β1-stimulated fibrotic changes in HPMCs. Considering that
G9a-mediated H3K9me1 reportedly down-regulates transcriptional activity by forming het-
erochromatin, our data imply a link between transcriptional silencing and fibrosis. In cancer
research, several anti-cancer genes have been identified and their silencing leads to the devel-
opment of tumors. In addition, several anti-fibrotic genes have been reported, such as BMP-7,
klotho, and hepatocyte growth factor (HGF) [31–33, 24]. Although we previously found that
klotho, but not BMP-7 or HGF, is regulated by G9a-mediated H3K9me1 in human proximal
tubular cells (HK-2), we did not find expression of klotho in HPMCs (data not shown). Fur-
ther studies are needed to elucidate the precise mechanism by which H3K9me1-mediated
transcriptional silencing induces fibrosis.
We demonstrated that MGO induces G9a expression through the production of TGF-β1.
Although we examined whether MGO directly induces TGF-β1 expression, we did not observe
MGO-induced upregulation of TGF-β1 in HPMCs or THP-1 cells (S2 Fig). In addition to TGF-
β1, we investigated whether MGO increased the expression of tumor necrosis factor-α and
monocyte chemoattractant protein in HPMCs and THP-1 cells. However, we could not identify
the mechanism by which MGO induces inflammation (S2 Fig). A possible explanation is that
MGO is a precursor of advanced glycation end-products (AGEs) [34]. Increased AGEs may
cause inflammation through binding to their receptor [5]. In this study, several double-positive
cells for CD68 and TGF-β1 were observed in the submesothelial compact zone. These findings
suggest that AGEs induce production of TGF-β1 through activation of inflammatory cells.
In summary, the present data show that TGF-β1 induces G9a, and that G9a-mediated
H3K9me1 has major roles in the progression of peritoneal fibrosis. We also show G9a expres-
sion in PD patients, although the sample size is small. Furthermore, BIX01294, a G9a inhibitor,
attenuates peritoneal fibrosis by suppression of H3K9me1 in MGO-induced mice. In the in
vitro experiments, BIX01294 treatment also inhibited TGF-β1-induced fibrotic changes by
suppression of H3K9me1 in HPMCs. These findings indicate that targeting G9a-mediated
H3K9me1 may be an effective strategy to prevent peritoneal fibrosis.
Supporting information
S1 Fig. Mitochondrial activity of HPMCs after treatment with BIX01294. We assessed the
cytotoxicity of BIX01294 at 1, 2, and 5 μM in HPMCs by the WST-1 assay that measures
G9a-induced H3K9me1 in peritoneal fibrosis
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mitochondrial activity. The graph shows mitochondrial activity in HPMCs treated with the
various doses of BIX01294. Data are expressed as the mean ± SE. Statistical analysis was per-
formed by analysis of variance followed by Tukey’s post-hoc test. P< 0.05, n = 5 samples per
group.
(DOCX)
S2 Fig. Expression of cytokines in HPMCs and THP-1 cells under MGO stimulation. Based
on previous reports [1, 2], we investigated the effect of MGO on cytokine expression in
HPMCs and THP-1 cells. Graphs show MGO-induced MCP-1 expression in HPMCs (a),
TNF-α expression in THP-1 cells (b), TGF-β1 expression in THP-1 cells (c) and HPMCs (d),
and mRNA expression of TGF-β1 in HPMCs (e). The initial MGO concentration of 100 μM
was selected based on the results of a previous report [1]. We tested higher doses of MGO, 100
and 200 μM, in subsequent experiments. Because 200 μM MGO had no effect on the TGF-β1
expression level and another report showing MGO-induced TGF-β1 expression used higher
levels of MGO [2], we tested the effects of 300–800 μM MGO on inducing TGF-β1 expression.
Lastly, TGF-β1 expression was evaluated by quantitative RT-PCR because it is more sensitive
and quantitative than measuring the protein level; this was performed on cells stimulated with
1 mM of MGO. Data are expressed as the mean ± SE. Statistical analysis was performed by
analysis of variance followed by Tukey’s post-hoc test. n = 5 samples per group.
(DOCX)
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